UVA School of Medicine emeritus professor Dr. Frederick G. Hayden helped design the trial and presented the results Wednesday ...

Treatments for dry eye disease, neuroendocrine tumors, chronic spontaneous urticaria, Barth syndrome, and migraine are under review.

Astellas Pharma’s strong pipeline and revenue growth support a positive outlook. See why ALPMF stock is a "Buy," driven by ...

A new combination pill has been given the green light by the National Institute for Health and Care Excellence (Nice) to ...

High-grade glioma, an aggressive form of pediatric and adult brain cancer, is challenging to treat given the tumor location, ...

But what if you could avoid getting COVID-19 altogether? That’s the potential promise of a new study on a drug made by Japanese pharmaceutical company Shionogi. At a scientific conference in San ...

Positive data from a pair of acute pain studies convinced the company that its drug, which works differently than existing ...

Specialty pharmaceutical company PharmaTher Holdings’ drug application for Ketamine has received a June 4 approval goal date, advancing approval of the drug in the U.S. PharmaTher said it is ...

The FDA has approved two new biosimilars of denosumab for all indications of the reference medications Prolia and Xgeva, ...

Optum Rx, the pharmacy benefit manager owned by UnitedHealth Group, placed Journavx on some of its commercial formularies in ...

Patients enroll in phase 2 oncology trials seeking access to promising new treatments, but the risk-benefit assessments and ...

The study, published March 12 in JAMA Network Open, compared the newly approved tenecteplase in a single quick injection to alteplase, the stroke treatment that has been used for decades and requires ...